869185-85-3

基本信息
SB 203580, Hydrochloride - CAS 869185-85-3 - Calbiochem
RWJ 64809 HYDROCHLORIDE
SB203580 HYDROCHLORIDE
SB-203580 HYDROCHLORIDE
物理化学性质
储存条件 | -20C |
溶解度 | insoluble in EtOH; insoluble in H2O; ≥20.7 mg/mL in DMSO |
形态 | 亮黄色固体 |
颜色 | Light yellow to yellow |
水溶解性 | Soluble to 25 mM in water |
稳定性 | 吸湿性 |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
海关编码 | 2933399990 |
SB 203580盐酸盐价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-10256A | SB 203580盐酸盐 Adezmapimod hydrochloride | 869185-85-3 | 5 mg | 330元 |
2025/02/08 | HY-10256A | 869185-85-3 Adezmapimod hydrochloride | 869185-85-3 | 10mM * 1mLin DMSO | 363元 |
2025/02/08 | HY-10256A | 869185-85-3 Adezmapimod hydrochloride | 869185-85-3 | 10mg | 600元 |
常见问题列表
p38 50 nM (IC 50 ) |
p38β2 500 nM (IC 50 ) |
SB 203580 (preincubated with 0-30 μM for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2) prevents the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC
50
of 3-5 μM.
SB203580 blocks PKB phosphorylation (IC
50
3-5 μM). SB203580 inhibitsthe phosphorylation of Ser473 in a dose-dependent manner in both CT6 and activated human T cells and IL-2-responsive BA/F3 F7 B cells.
Cell Proliferation Assay
Cell Line: | CT6, BA/F3 cell line F7, and PBMC/T cells |
Concentration: | 0-30 μM |
Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2 |
Result: | Prevented the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC 50 of 3-5 μM. |
Western Blot Analysis
Cell Line: | CT6 cells, activated human T cells, and BA/F3 F7 cells |
Concentration: | 0-30 μM |
Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h before stimulating with 20 ng/mL IL-2 for 5 min |
Result: | Inhibited the phosphorylation of PKB at Ser473 in a dose-dependent manner. |
SB203580 (5 mg/kg/day; intra peritoneal injected daily for 16 consecutive days, in female atymic Nu/Nu mice) treatment, p38WT tumors show a significantly smaller tumor burden when compared with p38TM tumors that were treated in parallel.
Animal Model: | Six-week-old female atymic Nu/Nu mice CAL27 p38WT and p38TM tumors |
Dosage: | 5 mg/kg/day |
Administration: | Intra peritoneal injected daily for 16 consecutive days |
Result: | After 2 weeks treatment, CAL27 p38WT tumors were significantly smaller; CAL27 p38TM tumors were not affected by the p38 inhibitor (n=10). |